Absci (ABSI) news

ABSCI Corp: Morgan Stanley raises target price to $10.00 from $4.10

ABSCI Corp (NASDAQ: ABSI) has seen recent analyst activity, with Morgan Stanley revising its price target for the stock. The firm raised its target price to $10.00 from $4.10, maintaining an "Equal Weight" rating on the shares. This adjustment reflects a growing interest in the company’s pipeline…

ImportantABSCI Corp shares jump 37% after co reports early-stage trial data from its AI-designed hair loss drug

ImportantABSCI Corp shares up 14% premarket after co reports early-stage trial data from its AI-designed hair loss drug

Eli Lilly & Company and others participate in $100 mln Absci Corp offering

Eli Lilly & Company has joined a $125 million crossover financing round for AbSci Corp, a synthetic biology company focused on biologic drug discovery and development. The round was co-led by existing investors Casdin Capital and Redmile Group, with additional participation from Fidelity Management…

ABSCI prices 13.5M shares of common stock at $7.41/share